Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News


Persistence pays off: After 8‑year follow-up, study finds robust and sustained antidepressant response to deep brain stimulation (DBS)


Long-Term Fol­low-Up Data Shows Deep Brain Stim­u­la­tion Is an Effec­tive Treat­ment for Treat­ment-Resis­tant Depres­sion (Mount Sinai press release):

A study pub­lished online on Fri­day, Octo­ber 4, in The Amer­i­can Jour­nal of Psy­chi­a­try found that deep brain stim­u­la­tion (DBS) of an area in the brain called the sub­cal­los­al cin­gu­late (SCC) pro­vides a robust anti­de­pres­sant effect that is sus­tained over a long peri­od of time in patients with treat­ment-resis­tant depres­sion—the most severe­ly depressed patients who have not respond­ed to oth­er treat­ments.

The long-term data pre­sent­ed in this study, con­duct­ed at Emory Uni­ver­si­ty and led by Helen S. May­berg, MD, now Pro­fes­sor of Neu­rol­o­gy, Neu­ro­surgery, Psy­chi­a­try, and Neu­ro­science, and Found­ing Direc­tor of the Nash Fam­i­ly Cen­ter for Advanced Cir­cuit Ther­a­peu­tics at the Icahn School of Med­i­cine at Mount Sinai, val­i­dates ear­li­er work con­duct­ed by the research team and lays the foun­da­tion for addi­tion­al stud­ies to refine and opti­mize DBS for these patients.

Deep brain stim­u­la­tion, cur­rent­ly approved by the U.S. Food and Drug Admin­is­tra­tion to treat essen­tial tremor, Parkinson’s dis­ease, epilep­sy, and obses­sive-com­pul­sive dis­or­der, is a neu­ro­sur­gi­cal pro­ce­dure involv­ing the place­ment of a neu­rostim­u­la­tor (some­times referred to as a “brain pace­mak­er”), which sends high-fre­quen­cy elec­tri­cal impuls­es through implant­ed elec­trodes deep in the brain to spe­cif­ic brain areas respon­si­ble for the symp­toms of each dis­or­der.

Dr. May­berg led the first tri­al of DBS of the sub­cal­los­al cin­gu­late white mat­ter, known as Brod­mann Area 25, for treat­ment-resis­tant depres­sion patients in 2005, demon­strat­ing that it could have clin­i­cal ben­e­fit. Sub­se­quent small open-label tri­als pro­duced sim­i­lar­ly favor­able results, yet despite these encour­ag­ing open-label results, a mul­ti-cen­ter, ran­dom­ized tri­al was halt­ed ear­ly due to a lack of sta­tis­ti­cal­ly sig­nif­i­cant anti­de­pres­sant response at the des­ig­nat­ed, six-month a pri­ori time point.

Despite the fact that larg­er tri­als were halt­ed ear­ly, what my col­leagues and I were see­ing as we con­tin­ued to fol­low patients from our ini­tial tri­als was that over time, they were get­ting bet­ter and not only that, they were stay­ing bet­ter. So we stayed the course,” says Dr. May­berg. “Over eight years of obser­va­tion, most of our study par­tic­i­pants expe­ri­enced an anti­de­pres­sant response to the deep brain stim­u­la­tion of Area 25 that was robust and sus­tained. Giv­en that patients with treat­ment-resis­tant depres­sion are high­ly sus­cep­ti­ble to recur­rent depres­sive episodes, the abil­i­ty of DBS to sup­port long-term main­te­nance of an anti­de­pres­sant response and pre­ven­tion of relapse is a treat­ment advance that can mean the dif­fer­ence between get­ting on with your life or always look­ing over your shoul­der for your next debil­i­tat­ing depres­sive episode.”

The Study:

Long-Term Out­comes of Sub­cal­los­al Cin­gu­late Deep Brain Stim­u­la­tion for Treat­ment-Resis­tant Depres­sion (Amer­i­can Jour­nal of Psy­chi­a­try). From the abstract:

  • Objec­tive: Deep brain stim­u­la­tion of the sub­cal­los­al cin­gu­late (SCC DBS) has been stud­ied as a poten­tial treat­ment for severe and refrac­to­ry major depres­sive dis­or­der since 2005. The authors used an open-label, long-term fol­low-up design to exam­ine par­tic­i­pants enrolled in a clin­i­cal tri­al of SCC DBS for treat­ment-resis­tant depres­sion.
  • Meth­ods: Long-term out­come data were col­lect­ed for 28 patients (20 with major depres­sive dis­or­der and sev­en with bipo­lar II dis­or­der; one patient in the major depres­sion sub­group was lat­er reclas­si­fied as hav­ing bipo­lar II dis­or­der) receiv­ing SCC DBS for 4–8 years.
  • Results: Response and remis­sion rates were main­tained at 50% and 30%, respec­tive­ly, through years 2–8 of the fol­low-up peri­od. Three-quar­ters of all par­tic­i­pants met the treat­ment-response cri­te­ri­on for more than half of their dura­tion of par­tic­i­pa­tion in the study, with 21% of all patients demon­strat­ing con­tin­u­ous response to treat­ment from the first year onward. Of 28 par­tic­i­pants, 14 com­plet­ed ?8 years of fol­low-up, 11 com­plet­ed 4 years, and three dropped out before 8 years. The pro­ce­dure itself was gen­er­al­ly safe and well tol­er­at­ed, and there were no side effects of acute or chron­ic stim­u­la­tion. The rate of med­ical or sur­gi­cal com­pli­ca­tions was con­sis­tent with the rate observed in stud­ies of DBS for oth­er indi­ca­tions. There were no sui­cides.
  • Con­clu­sions: In >8 years of obser­va­tion, most par­tic­i­pants expe­ri­enced a robust and sus­tained anti­de­pres­sant response to SCC DBS.

News in Context:

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Cognitive Neuroscience, Health & Wellness, Technology

Tags: , , , , , , , , ,

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters,  SharpBrains is an independent market research firm tracking how brain science can improve our health and our lives.

Search in our archives

Follow us and Engage via…

RSS Feed

Watch All Recordings Now (40+ Speakers, 12+ Hours)